



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/032,162	12/21/2001	James M. Binley	59331-AZ/JPW/SHS	5928

7590 11/29/2005  
John P. White  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, NY 10036

EXAMINER

PARKIN, JEFFREY S

ART UNIT	PAPER NUMBER
----------	--------------

1648

DATE MAILED: 11/29/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Interview Summary</b>	Application No. 10/032,162	Applicant(s) BINLEY ET AL.	
	Examiner Jeffrey S. Parkin, Ph.D.	Art Unit 1648	

All participants (applicant, applicant's representative, PTO personnel):

(1) Jeffrey S. Parkin, Ph.D. (3) \_\_\_\_\_

(2) Ashton J Delauney (4) \_\_\_\_\_

Date of Interview: 22 November 2005.

Type: a) ☒ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.  
If Yes, brief description: \_\_\_\_\_

Claim(s) discussed: N/A.

Identification of prior art discussed: N/A.


Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☒ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

  
Examiner's signature, if required

## Summary of Record of Interview Requirements

### Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

### Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

#### Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

#### 37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiner's Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,  
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

### Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicants' representative contacted the examiner and stated that they never received copies of the signed IDSs submitted 14 August, 2004. Applicants were advised that these statements were previously considered in the communication dated 29 June, 2005 (a copy of which is attached to the interview summary). Therefore, ALL formal matters were previously addressed by the examiner and the application should be processed by the office of publications in a timely manner.



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/032,162	12/21/2001	James M. Binley	59331-AZ/JPW/SHS	5928
7590	07/05/2005			
EXAMINER				
PARKIN, JEFFREY S				
ART UNIT		PAPER NUMBER		
1648				

DATE MAILED: 07/05/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

DEAFCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
10/032,162	12/21/2001	Binley, J. M., et al.	

EXAMINER	
Jeffrey S. Parkin, Ph.D.	
ART UNIT	PAPER NUMBER
1648	29 June, 2005

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application  
Commissioner of Patents

**37 C.F.R. § 1.84**

The drawings filed in this application on 01 October, 2004, are not objected to by the Draftsperson under 37 C.F.R. § 1.84 or § 1.152 and are deemed appropriate.

**37 C.F.R. § 1.98**

The information disclosure statements filed 16 August, 2004, have been placed in the application file and the information referred to therein has been considered.

**Post-Allowance Correspondence**

All post-allowance correspondence concerning this application should be mailed to the following address:

BOX ISSUE FEE  
COMMISSIONER FOR PATENTS  
WASHINGTON, DC 20231

Alternatively, post-allowance communications (i.e., 37 C.F.R. § 1.312 amendments, formal drawings, etc.) can be faxed to the OFFICE OF PATENT PUBLICATIONS at (703) 308-5083 to facilitate their expeditious handling. Do not send post-allowance communications to the Technology Center since this will result in paper matching delays.

For information concerning the status of an allowed application and other matters please contact the appropriate branch as follows:

- Status of correspondence after receipt of the Notice of Allowance: contact the Correspondence Branch at (703) 305-8027.

- Notices of Abandonment for failure to pay the issue fee or failure to submit formal drawings: contact (703) 305-5358 or (703) 305-5340.


5.00

- Issue fees that have not been paid in at least 3 months, but no issue notification has been received: contact (703) 305-8263.
- Failure to receive the Letters of Patent: contact (703) 305-8263.
- Application status after payment of the issue fee, status of issue fee payment, status of receipt of issue fee, status of allowed applications after receipt of the drawings or fees, and application status after receipt of formal drawings after allowance: contact Customer Service at one of the following numbers: (888) 786-0101, (703) 308-6789, (703) 305-8497, (703) 305-8495, and (703) 308-6790.

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, James C. Housel, can be reached at (571) 272-0902. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Formal communications may be submitted through the official facsimile number which is (703) 872-9306. Hand-carried formal communications should be directed toward the customer window located in Crystal Plaza Two, 2011 South Clark Place, Arlington, VA. Applicants are directed toward the O.G. Notice for further guidance. 1280 O.G. 681. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,



Jeffrey S. Parkin, Ph.D.  
Primary Examiner  
Art Unit 1648

29 June, 2005



<b>U.S. Department of Commerce Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)						<b>Atty. Docket No.</b> 59331-AZ /JPW/MAF/DJK		<b>Serial No.</b> 10/032,162					
						<b>Applicant(s)</b> James L. Binley et al.							
						<b>Filing Date</b> December 21, 2001		<b>Group Art Unit</b> 2632					
<b>U.S. PATENT DOCUMENTS</b>													
<b>Examiner Initials</b>		<b>Document Number</b>						<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>	
<b>FOREIGN PATENT DOCUMENTS</b>													
		<b>Document Number</b>						<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>	
												<b>Yes</b>	<b>No</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
		Binley, J., et al., (2000) "A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized By An Intermolecular Disulfide Bond Between The GP 120 and GP 41 Subunits Is An Antigenic Mimic Of The Trimeric Viron-Associated Structure", Journal of Virology, Vol. 74, No. 2, 627-643 ( <b>Exhibit B</b> )											
		Farzan, M., et al. (1998) "Stabilization Of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers By Disulfide Bonds Introduced Into The GP 41 Glycoprotein Ectodomain", Journal of Virology, Vol. 72, No. 9, 7620-7625 ( <b>Exhibit C</b> )											
<b>EXAMINER</b>								<b>DATE CONSIDERED</b> 12/12/03					
<small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>													

RECEIVED

APR 30 2003

Technology Center 2600

RECEIVED

MAY 05 2003

TECH CENTER 1600/2900





Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
59331-  
AZ/JPW/MAF/AJDSerial No.  
10/032,162Applicant(s)  
James M. Binley et al.Filing Date  
December 21, 2001Group Art Unit  
2632INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date <small>If Appropriate</small>
	5 8 8 6 1 6 3	3/23/99	Binley et al.			<b>RECEIVED</b> JUL 17 2003 Technology Center 2600

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Burton, D.R. et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027;
	Labranche, C.C. et al. (1994) Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus. J. Virol. 68(9): 5509-5522;
	Labranche, C.C. et al. (1994) Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus. J. Virol. 68(11): 7665-7667;
	Trkola, A. et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70(2): 1100-1108.

**RECEIVED**  
JUL 18 2003  
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

12/12/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**BEST AVAILABLE COPY**

Sheet 1 of 2

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Atty. Docket No.</b> 59331-AZ JPW/MAF/AJD		<b>Serial No.</b> 10/032,162	
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				<b>Applicant(s)</b> James L. Binley et al.			
				<b>Filing Date</b> December 21, 2001		<b>Group Art Unit</b> 2632 16488	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>		<b>Document Number</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
		5 9 3 5 5 7 9	08/10/99	Habeshaw, J.A. et al.			
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>Document Number</b>	<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>
							Yes No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
		Arwell, S. et al. (1997) Stable Heterodimers form Remodeling the Domain Interface of a Homodimer using a Phage Display Library, J. Mol. Biol. 270: 26-35;					
		Barouch, D.H. and N.L. Letvin (2000) DNA Vaccination for HIV-1 and SIV, Interviro. 4: 282-287;					
		Barouch, D.H. et al. (2002) Eventual AIDS Vaccine Failure in a Rhesus Monkey by Viral Escape from Cytotoxic T Lymphocytes, Nature 415: 335-339;					
		Burton, D.R. and J.P. Moore (1998) Why do we Not Have an HIV Vaccine and how Can we Make One? Nature Med. Vaccine Suppl. 4(5): 495-498;					
		Cao, J. et al. (1997) Replication and Neutralization of Human Immunodeficiency Virus Type 1 Lacking the V1 and V2 Variable Loops of the gp120 Envelope Glycoprotein, J. Virol. 71: 9808-9812;					
		Edinger, A.L. et al. (1999) Functional Dissection of CCR5 Coreceptor Function through the Use of CD4-Independent Simian Immunodeficiency Virus Strains, J. Virol. 73: 4062-4073;					
		Fouts, T.R. et al. (1998) Interactions of Polyclonal and Monoclonal Anti-Glycoprotein 120 Antibodies with Oligomeric Glycoprotein 120-Glycoprotein 41 Complexes of a Primary HIV Type 1 Isolate: Relationship to Neutralization, AIDS Res. Human Retrovir. 14: 591-597;					
		Fouts, T.R. et al. (1997) Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human Monoclonal Antibodies Correlates with Antibody Binding to the Oligomeric Form of the Envelope glycoprotein Complex, J. Virol. 71: 2779-2785;					
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			
				06/29/05			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

**BEST AVAILABLE COPY**

Sheet 2 of 2

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 59331-AZ /JPW/MAF/AJD	Serial No. 10/032,162
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant(s) James L. Binley et al.	
				Filing Date December 21, 2001	Group Art Unit 2632/648
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
		Gallagher, W.R. et al. (1995) A General Model for the Surface Glycoproteins of HIV and Other Retroviruses, AIDS Res. Human Retrovir. 11: 191-202;			
		Helseth, E. et al. (1991) Human Immunodeficiency Virus Type 1 gp120 envelope Glycoprotein Regions Important for Association with the gp41 Transmembrane Glycoprotein, J. Virol. 65(4): 2119-2123;			
		Haynes, B.F. (1996) HIV Vaccines: Where are we and Where are we Going? Lancet 348: 933-937;			
		Johnston, M.J. and J. Flores (2001) Progress in HIV Vaccine Development, Curr. Opin. Pharmacol. 1(5): 504-510;			
		Joy, A.K. et al. (1999) Can HIV Infection be Prevented with a Vaccine? Drugs R&D 6: 431-440;			
		Maerz, A.L. et al. (2001) Functional Analysis of the Disulfide-Bonded Loop/Chain Reversal Region of Human Immunodeficiency Virus Type 1 gp41 reveals a Critical Role in gp120-gp41 Association, J. Virol. 75(14): 6635-6644;			
		McInerney, T.L. et al. (1998) Mutation-Directed Chemical Cross-Linking of Human Immunodeficiency Virus Type 1 gp41 Oligomers, J. Virol. 72: 1523-1533;			
		Mitchell, W.M. et al. (1998) Inactivation of a Common Epitope Responsible for the Induction of Antibody-Dependent Enhancement of HIV, AIDS 12: 147-156;			
		Moore, J.P. et al. (1994a) "Probing the Structure of the Human Immunodeficiency Virus Surface Glycoprotein gp120 with a Panel of Monoclonal Antibodies, J. Virol. 68: 469-484;			
		Moore, J.P. et al. (1994b) Immunological Evidence for Interactions between the First, Second, and Fifth Conserved Domains to the gp120 Surface Glycoprotein of Human Immunodeficiency Virus Type 1, J. Virol. 68(11): 6836-6847;			
		Murphy, F.A. (1996) "Virus Taxonomy," in Fields Virology, Third Edition, Fields, B.N., et al. eds., Lippincott-Raven Publisher, Philadelphia, pp. 40 and 41;			
		Parren, P.W. et al. (1997) HIV-1 Antibody - Debris or Virion? Nat. Med. 3: 366-367;			
		Parren, P.W. et al. (1998) Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity, J. Virol. 72: 3512-3519;			
		Reitter, J.N. et al. (1998) A Role for Carbohydrates in Immune Evasion in AIDS, Nat. Med. 4: 679-684;			
		Schulz, T.F. et al. (1992) Conserved Structural Features in the Interaction between Retroviral Surface and Transmembrane Glycoproteins? AIDS Res. Hum. Retrovirus 8(9): 1571-1580; and			
		Stamatatos, L. et al. (1994) Differential Regulation of Cellular Tropism and Sensitivity to Soluble CD4 Neutralization by the Envelope gp120 of Human Immunodeficiency Virus Type 1, J. Virol. 68: 4973-4979.			
EXAMINER		DATE CONSIDERED 06/29/05			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
59331-AZ  
JPW/AJD/BWSLSerial No.  
10/032,162INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicant(s)  
James M. Binley et al.Filing Date  
December 21, 2001Art Unit  
1648

## U.S. PATENT DOCUMENTS

Examiner Initials	Exh No.	Document Number								Date	Name	Class	Subclass	Filing Date If Appropriate
<i>[Signature]</i>	1	6	1	7	1	5	9	6		01/09/01	Earl et al.			

## FOREIGN PATENT DOCUMENTS

		Document Number								Date	Country	Class	Subclass	Translation	
														Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

\*EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



*06/29/05*

